Myanmar Clinical Practice Guideline for Osteoporosis

Authors

  • Than Than Aye Department of Medicine, University of Medicine (2), Yangon, Myanmar
  • Ko Ko Department of Medicine, University of Medicine (2), Yangon, Myanmar
  • Thein Myint Department of Medicine, University of Medicine (2), Yangon, Myanmar
  • Ni Ni Hlaing Department of Medicine, University of Medicine (2), Yangon, Myanmar
  • Myint Thaung Department of Orthopedic, University of Medicine (2), Yangon, Myanmar
  • Tet Tun Chit Consultant Physician, East Yangon General Hospital, Yangon, Myanmar

Abstract

Osteoporosis is a disease in which the density and quality of bone are reduced, leading to weakness of the skeleton and increased risk of fracture, particularly of the spine, wrist and hip.

 

Generally, osteoporosis in Myanmar is still a neglected disease entity in the national priority health problems. Due to the low level of awareness on osteoporosis and its consequent fragility fractures, limited availability and accessibility of standard diagnostic tools and medications, osteoporosis is mainly under diagnosed and under-treated in daily clinical practice. It is not mentioned in the prioritized diseases in the national health plan.

Downloads

Download data is not yet available.

References

Aasis Unnanuntana, Brian P. Gladnick, Eve Donnely. Joseph M. Lane. Current Concept review: The assessment of Fracture risk; J Bone Joint Surg Am. 2010;92:743-53

Apley, AG, (2010), Apley's System of Orthopaedics and Fracture, 9th ED. P131-135. New York: Hodder Arnold

Barrett-Connor E, Mosca L, Collins P, et al; Raloxifene Use for The Heart (RUTH) Trial Investigators.

Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucii E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA.2005;293:2257–2264.

Black DM, Delmas PD, Eastell R, et al. Once-yearly zolendronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356:180–1822.

Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment. JAMA.2006;296:2927–2938.

Chesnut CH, Silverman S, Andriano K, et al, for the PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med. 2000;109:267–276.

Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men. The Royal Australian College of General Practitioners, February 2010.

Consensus Development Conference: prophylaxis and treatment of osteoporosis. American Journal of Medicine: 1991:90:107-10

Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:517–523.

Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:540–551.

Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:508–516.

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 335:125–137.

Fujiwara S, Nakamura T, Orimo T.H, Hosoi I, Gorai I, Oden H.A, Johansson H, Kanis J.A Development and application of a Japnes model of the WHO Fracture Risk assessment tool (FRAX TM): Osteoporosis Int (2008) 19:429-435

Genant HK, Engelke K, Fuerst T, Gluer CC, Grampp S, Harris ST, Jergas M, Lang T, Lu Y, Majumdar S, Mathur A, Takada M. Non-invasive assessment of bone mineral and structure: State of the art, JBone Miner Res, 19996;11:707-730

Health in Myanmar 2012

Health in Myanmar Statistics 2011

Johansson H, Kanis J. A, Oden A, Johnnell O, McCloskey E. BMD, clinical risk factors and their combination for hip fracture prevention.

Lau EMC, SambrookP,SeemanE,Leong KH, Leung PC and Delmas P. Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia. APLAR Journal of Rheumatology 2006; 9: 24–36.

Li-Yu J, Perez EC, Canete A, Bonifacio L, Llamado LQ, Martinez R, Lanzon A and Sison M. Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. International Journal of Rheumatic Diseases 2011; 14: 223–238.

Myanmar Medical Association, Special Interest Group on Osteoporosis. Unpublished data on prevalence of osteoporosis in Yangon, Myanmar, 2009.

National Institute of Health (United States) Consensus conference, 2000

National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010.

NICE guidelines for Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended). www.nice.org.uk/guidance/TA161

NICE guidelines for Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended). www.nice.org.uk/guidance/TA16

Ostoeporosis Guideline of Malaysia, Thailand, USA

Osteoporosis Screening, Diagnosis and Treatment Guideline in United States: https//www.ghc.org/all-sites/guidelines/osteoporosis.pdf

Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary CMAJ2010; 182(17):1864-1873.

Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305:783–789

Performance of Osteoporosis Self-assess DAJ Muslim, EF Mohd, AY Sallehudin, TMS TengkuMuzaffar,AM Ezane, MMED Radment Tool for Asian (OSTA) for Primary Osteoporosis in Post-menopausal Malay Wome, Malaysian Orthopaedic Journal 2012 Vol 6 No 1

Summary Meeting Report, Brussels, Belgium, 5-7 May 2004.

WHO scientific group on the assessment of osteoporosis at primary health care level

WHO (1994) Assessment of Fracture risk and its application to screening for post menopausal osteoporosis (WHO technical report series, No. 843)

WHO (2003) Prevention and management of osteoporosis ( WHO technical report series, No. 921)

Downloads

Published

2014-05-22

How to Cite

Aye, T. T., Ko, K., Myint, T., Ni Hlaing, N., Thaung, M., & Tun Chit, T. (2014). Myanmar Clinical Practice Guideline for Osteoporosis. Journal of the ASEAN Federation of Endocrine Societies, 27(2), 151. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/29

Issue

Vol. 27 No. 2 (2012): November Issue

Section

Feature Articles

License

Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).

To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.

A written agreement shall be emailed to the requester should permission be granted.